Spark Gets FDA Greenlight for Luxturna, The First Gene Therapy for Eye Disease Approved in the U.S. Post author:Sam Post published:December 18, 2017 Post category:BioPharma The FDA broke new ground today with a first-of-its-kind therapy for eye disease. Source: BioSpace You Might Also Like A Look Inside Takeda's Remarkable R&D Transformation February 26, 2017 The Stunning Golden Parachutes of Juno's $9B Celgene Deal February 4, 2018 NeuralStem Announces Pricing Of Public Offering Of Common Stock And Warrants July 26, 2017
